Related references
Note: Only part of the references are listed.Treatment Patterns in Patients With Prostate Cancer and Bone Metastasis Among US Community-based Urology Group Practices
Stephen J. Freedland et al.
UROLOGY (2012)
Treatment Persistence With Monthly Zoledronic Acid is Associated With Lower Risk and Frequency of Skeletal Complications in Patients With Breast Cancer and Bone Metastasis
Hind T. Hatoum et al.
CLINICAL BREAST CANCER (2011)
American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
Catherine H. Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population
N. V. Velde et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2011)
Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers
Henry J. Henk et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases
Henry J. Henk et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases - Analysis of a national medical claims database
Hind T. Hatoum et al.
CANCER (2008)
Use of intravenous bisphosphonates in older women with breast cancer
Sharon H. Giordano et al.
ONCOLOGIST (2008)
Patterns of bisphosphonate use in the united states in the treatment of metastatic bone disease
Joanne E. Mortimer et al.
CLINICAL BREAST CANCER (2007)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
